# 2026-16829: FDA Workshop: Testosterone for Menopausal Women? Hormone Norms Flipped!

2026-16829, Testosterone Use in Menopausal Women; Public Workshop; Request for Comments, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-18, effective 2026-09-17 (as of 2026-08-25).

- Canonical: https://policyrisk.com/federal-register/2026-16829
- As of: 2026-08-25
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16829
- Title: Testosterone Use in Menopausal Women; Public Workshop; Request for Comments
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53417
- Published: 2026-08-18
- Effective: 2026-09-17
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-25

## In one line

FDA Workshop: Testosterone for Menopausal Women? Hormone Norms Flipped!

## Summary

The Food and Drug Administration's (FDA) Office of Women's Health and the Center for Drug Evaluation and Research are announcing a public workshop titled "Testosterone Use in Menopausal Women." The purpose of the public workshop is to examine the current scientific evidence and critical knowledge gaps related to testosterone use in menopausal women to help inform future research and potential drug development of testosterone products for menopausal women. Researchers, educators, industry, clinicians, patients, and consumers may benefit from attending this scientific workshop. Presentations will examine the physiological roles of testosterone throughout a woman's life, including age-related decline, the menopausal transition, challenges associated with measuring and interpreting testosterone blood levels, and how these levels correlate with clinical symptoms and conditions. Speakers will review current and potential clinical uses of testosterone in menopausal women and examine the strengths and limitations of available data supporting those uses. Speakers will discuss regulatory considerations, including the development of robust efficacy and safety data, to support a marketing application for testosterone in menopausal women for the treatment of various clinical conditions, and study design considerations for evaluating long-term safety outcomes in women.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16829 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/18/2026-16829/testosterone-use-in-menopausal-women-public-workshop-request-for-comments)
- [2026-16829 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-18/pdf/2026-16829.pdf)

## Related
- [Previous: 2026-16827, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-16827)
- [Next: 2026-16830, Self-Regulatory Organizations; NYSE American LLC; Notice of Filing of Amendment…](https://policyrisk.com/federal-register/2026-16830)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16829 (as of 2026-08-25).
